Ascentage Pharma Presents Updated Olverembatinib Data for CML-CP at ASCO 2026

Ascentage Pharma shared updated clinical trial results for its drug olverembatinib at the 2026 ASCO Annual Meeting. The data, focusing on second-line treatment for chronic-phase chronic myeloid leukemia, demonstrated sustained anti-tumor activity. Patients showed high response rates and a manageable safety profile, indicating potential benefits for this patient population.